Keele Research Repository

Article

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, RD, Park, YH, Hall, PS, Perren, T, Stein, RC, Mangel, L, Ferrero, J-M, Phillips, M, Conibear, J, Cortes, J, Foxley, A, de Bruin, EC, McEwen, R, Stetson, D, Dougherty, B, Sarker, S-J, Prendergast, A, McLaughlin-Callan, M, Burgess, M, Lawrence, C, Cartwright, H, Mousa, K and Turner, NC (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). 423 - 433.

Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.

Conference or Workshop Item

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, M ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, R, Park, YH, Hall, P, Perren, T, Stein, RC, Laszlo, M, Ferrero, J-M, Phillips, M, Conibear, J, Sarker, S-J, Prendergast, A, Cartwrightx, H, Mousa, K and Turner, NC (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. In: 2018 ASCO Annual Meeting I, 01-05 Jun 2018.